Cancer Treatment: Türkiye vs. U.S. — A Full Cost Comparison (2026)

A cancer diagnosis is not just a medical crisis — for millions of American families, it is a financial one. U.S. cancer treatment costs have risen faster than almost any other category of healthcare, pushing patients to look for high-quality care beyond their borders. Türkiye has become one of the most credible options. This guide breaks down the real numbers, side by side, and shows what the total picture actually looks like.

Why cost differs so dramatically

The price gap between American and Turkish oncology care is not because Türkiye is cutting corners. It comes down to four structural factors:

• Labor costs. A senior oncologist salary in Türkiye is roughly one third of the U.S. equivalent — even at top private hospitals.
• Real-estate and facility costs. Land, construction, and hospital operating overheads are far lower.
• No middlemen. The U.S. cost of care includes insurers, PBMs, and administrative layers that add 20–30% on top of the medical bill. Türkiye's cash-price model skips this entirely.
• Drug and device pricing. The same Roche or Bristol-Myers oncology drug can cost 60% less in Türkiye than in the U.S. — the manufacturer prices differently by market.

Chemotherapy: side-by-side cost

A standard six-cycle chemotherapy protocol for early-stage breast cancer (AC-T regimen) illustrates the pattern:

• United States (in-network): $90,000 – $180,000 total. Out-of-pocket after insurance still commonly $8,000 – $20,000.
• Türkiye (top JCI hospital, cash package): $18,000 – $32,000 all-in, including the drugs, infusion suite, oncologist visits, and standard supportive care.

For targeted therapies like trastuzumab (Herceptin) for HER2-positive breast cancer, the gap is even wider — annual drug costs alone are typically $80,000 in the U.S. versus $25,000 – $35,000 in Türkiye.

Radiotherapy and proton therapy

Standard external-beam radiotherapy (25–30 sessions) for breast or prostate cancer costs $25,000 – $50,000 in the U.S., versus $6,000 – $12,000 in Türkiye. For proton therapy — a premium modality used for pediatric tumors and select adult cases — the U.S. list price runs $100,000 – $200,000; Türkiye's Acıbadem Altunizade proton center, one of the few in the region, offers full courses for $50,000 – $80,000.

Surgery: robotic and open

• Robotic prostatectomy (da Vinci): U.S. $40,000 – $70,000 · Türkiye $12,000 – $18,000
• Mastectomy with reconstruction: U.S. $50,000 – $100,000 · Türkiye $14,000 – $22,000
• Colorectal resection: U.S. $35,000 – $70,000 · Türkiye $10,000 – $16,000

Immunotherapy and CAR-T

Immunotherapies like pembrolizumab (Keytruda) and nivolumab (Opdivo) list at $150,000 – $250,000 per year in the U.S., versus $45,000 – $80,000 in Türkiye. CAR-T cell therapy — the breakthrough treatment for certain blood cancers — costs $475,000 for the drug alone in the U.S. (Yescarta, Kymriah), often exceeding $1 million with hospitalization. Türkiye's CAR-T programs, including at Memorial and Acıbadem, deliver the same FDA-approved products at total costs of $180,000 – $260,000.

What's not in the sticker price

An honest cost comparison must include travel, lodging, and the softer costs of leaving home for weeks:

• Round-trip flights (patient + companion): $1,500 – $3,000
• Accommodation for 4–6 weeks: often included in coordinated packages, otherwise $2,000 – $5,000
• Meals, ground transport, incidentals: $1,500 – $3,000
• Time off work — usually the biggest hidden cost

Real total cost example

For a stage II breast cancer patient needing surgery, chemotherapy, radiation, and one year of trastuzumab:

United States (out-of-pocket after typical insurance): $35,000 – $65,000
Türkiye (all-inclusive care package with travel): $55,000 – $75,000
United States (uninsured): $250,000 – $500,000

For an insured U.S. patient, the numbers are closer than you might think — the value of going abroad depends on your specific plan, deductible, and out-of-pocket maximum. For an uninsured or underinsured patient, Türkiye can mean the difference between treatment and no treatment.

Does cheaper mean lower quality?

No, and this is the point most patients need to hear. JCI-accredited Turkish hospitals like Acıbadem, Memorial, Medical Park, and Koç use the same equipment (Varian, Elekta, Intuitive), follow the same NCCN and ESMO treatment guidelines, and staff their oncology departments with physicians who often trained at Sloan Kettering, MD Anderson, Dana-Farber, or leading European centers. Peer-reviewed outcomes data for common cancer surgeries and complex treatments are comparable to top U.S. programs. The savings come from lower structural costs, not lower standards.